Solid tumors meet their demands for nascent blood vessels and increased glycolysis, to combat hypoxia, by activating multiple genes involved in angiogenesis and glucose metabolism. Hypoxia inducible factor-1 (HIF-1) is a constitutively expressed basic helix-loop-helix transcription factor, formed by the assembly of HIF-1␣ and HIF-1␤ (Arnt), that is stablized in response to hypoxia, and rapidly degraded under normoxic conditions. It activates the transcription of genes important for maintaining oxygen homeostasis. Here, we demonstrate that engineered down-regulation of HIF-1␣ by intratumoral gene transfer of an antisense HIF-1␣ plasmid leads to the down-regulation of VEGF, and decreased tumor microvessel density. Antisense HIF-1␣ monotherapy resulted in the complete and permanent rejection of small (0.1 cm in diameter) EL-4 tumors, which is unusual for an anti-angiogenic agent where transient suppression of tumor
Introduction
Solid tumors must establish a blood supply and/or display enhanced glucose metabolism to grow beyond a few mm. 1 How they sense hypoxia, and respond by activating hypoxia-inducible genes and secreting angiogenic factors to establish a blood system is central to cancer biology, the answers to which will provide new strategies for cancer treatment. 2, 3 Many tumors contain hypoxic microenvironments, which have been associated with malignant progression, poor prognosis, metastasis and resistance to radiotherapy and chemotherapy. 1, 4, 5 The discovery of hypoxia-inducible factor-1 (HIF-1) gave an insight into the regulation of hypoxia-inducible genes.
1,6-8 HIF-1, which is formed by the assembly of HIF-1␣ and HIF-1␤ (Arnt) during hypoxia, 1,9,10 binds hypoxia-response elements (HREs) in enhancers of genes encoding angiogenic factors such as VEGF, and glycolysis-related proteins such as glycolytic enzymes, and glucose transporters 1 and 3 (Glut-1 and 3). [11] [12] [13] [14] The latter growth is the norm. It induced NK cell-dependent rejection of tumors, but failed to stimulate systemic T cell-mediated anti-tumor immunity, and synergized with B7-1-mediated immunotherapy to cause the NK cell and CD8 T cell-dependent rejection of larger EL-4 tumors (0.4 cm in diameter) that were refractory to monotherapies. Mice cured of their tumors by combination therapy resisted a rechallenge with parental tumor cells, indicating systemic antitumor immunity had been achieved. In summary, whilst intensive investigations are in progress to target the many HIF-1 effectors, the results herein indicate that blocking hypoxia-inducible pathways and enhancing NK-mediated antitumor immunity by targeting HIF-1 itself may be advantageous, especially when combined with cancer immunotherapy. Gene Therapy (2001) 8, 638-645.
proteins are required for the high glycolytic rates of cancer cells, and hence are important for the bioenergetics of tumor growth. HIF-1␣-deficiency is embryonically lethal resulting from impaired vascularization. 15 Embryonic stem cells lacking HIF-1␣ are unable to up-regulate several HIF-1 target genes under hypoxic or low glucose conditions, in particular enzymes in the glycolytic pathway. 15, 16 Loss of HIF-1␣ results in reduced hypoxiainducible expression of VEGF, failure to form new blood vessels, and retardation of solid tumor growth, 15 and conversely overexpression correlates with tumor growth. 17 HIF-1␣ is overexpressed in many tumor types compared with respective normal tissues, including colon, breast, gastric, lung, skin, ovarian, pancreatic, prostate and renal carcinomas. 17 Whereas HIF-1␤ is constitutively expressed, HIF-1␣ is rapidly degraded during normoxia by the ubiquitin-proteasome pathway, and dramatically stabilized and activated following hypoxia, by an oxygen-sensing and signalling process that remains an enigma. 18, 19 HIF-1␣ associates with pVHL (von Hippel-Lindau tumor-suppressor protein), 20, 21 and heat shock protein 90 (hsp90) 22, 23 that determine its fate. pVHL targets hypoxia-inducible factors including HIF-1␣ for oxygen-dependent proteolysis, and destabilizes VEGF and other hypoxically regu-lated mRNAs. 21, 24 In VHL-defective cells, HIF-1␣ is constitutively stabilized and activated, 21 resulting in inherited hypervascular tumors. 25 Downstream effectors of HIF-1, in particular VEGF, have been intensively investigated as targets for the treatment of solid vascular tumors, with some degree of success. Thus inhibition of VEGF expression in tumor xenografts leads to vascular regression, and decreased tumor growth. [26] [27] [28] We reasoned that the simplest means of inhibiting HIF-1 effectors responsible for tumor growth, would be to target HIF-1 itself. Here we demonstrate that HIF-1␣ is a suitable target to attack the tumor vasculature.
To date, the long-held promise of cancer immunotherapy has not been realized. We propose that cancer immunotherapy can be made more effective by simultaneously targeting a tumour's weapons of survival, defense and attack. We have previously shown that an attack on the tumor vasculature combined with B7-1 immunotherapy, which costimulates antitumor T cells and generates systemic antitumor immunity, overcomes the immuneresistance of large tumors. 29 Here we reveal that anti-HIF-1␣ therapy greatly enhances the therapeutic efficacy of cancer immunotherapy involving gene transfer of the T cell costimulator B7-1 into tumors in situ.
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Results
Gene transfer of an expression plasmid encoding antisense HIF-1␣ induces the rejection of established tumors EL-4 tumors of 0.1 cm in diameter were established in C57BL/6 mice, and injected with a DNA/liposome transfection vehicle containing 100 g of antisense HIF-1␣ pcDNA3B plasmid DNA. Immunohistochemical analysis of tumor sections prepared 2 days following gene transfer, revealed antisense therapy resulted in almost the complete inhibition of HIF-1␣ expressed endogenously in growing tumors (Figure 1 , compare c and d). Down-regulation of HIF-1␣ expression was confirmed by Western blot analysis of tumor homogenates (Figure 1i ). Tumor growth was monitored for 4 weeks following gene transfer (Figure 2a) . A comparison was made with mice treated with 100 g of empty vector control, and vector encoding the T cell costimulator B7-1 as a positive control. 30 Tumors grew rapidly in the control group, reaching 1 cm in size 14-17 days following gene transfer, whereas tumors treated with the antisense HIF-1␣ plasmid and B7-1 completely and rapidly regressed within 1 week of gene transfer. Mice remained tumor-free for a further 21-day period during which they were monitored. There was no significant difference between the growth pattern of tumors treated with B7-1 and antisense HIF-1␣ (P Ͼ 0.05). However, when antisense HIF-1␣-treated, tumor-free, mice were rechallenged with 1 × 10 6 parental EL-4 cells, palpable tumors appeared 15-20 days later in all the mice (Table 1 ). In contrast, no tumors emerged over a monitoring period of 2 months in mice that had cleared their tumors in response to B7-1 immunotherapy.
Antisense HIF-1␣ therapy does not eradicate large tumors, but slows their growth We have previously demonstrated that tumors become refractory to B7-1-mediated immunotherapy once they 30 To determine whether antisense HIF-1␣ therapy was similarly ineffective against large tumors, EL-4 tumors of 0.4 cm in diameter were established, and treated with 100 g antisense HIF-1␣ expression plasmid. As shown in Figure 2b , none of the mice rejected their tumors, albeit there was a significant (P Ͻ 0.01) inhibition of tumor growth, similar to that observed with B7-1 therapy. All tumors eventually reached 1 cm in diameter within 2 weeks, and mice had to be killed.
B7-1 mAb 1G10 (×100 magnification). (c-f) Down-regulation of HIF-1␣ and VEGF by antisense HIF-1␣ therapy. Tumors 0.1 cm in diameter were injected with DOTAP liposomes containing either empty vector (c, e), or antisense HIF-1␣ cDNA (d, f). Illustrated are representative tumor sections prepared 4 days following gene transfer, and stained brown with mAbs against HIF-1␣ (c, d), and VEGF (e, f) (×100 magnification). (g, h) Antisense HIF-1␣ therapy blocks the formation of new tumor blood vessels. Illustrated are sections prepared from 0.4 cm tumors injected 4 days earlier with either empty vector (pcDNA3) (g), or antisense HIF-1␣ (h). Endothelial cells within sections were stained with the anti-CD31 mAb, revealing tumor blood vessels (×10 magnification). Measurement of expression of HIF-1␣ (i) and VEGF (j) in tumor homogenates by Western blotting. Homogenates were prepared from tumors treated with empty plasmid (lanes 1), and plasmids encoding sense HIF-1␣ (lanes 2), and anti-sense HIF-1␣ (lanes 3). Blots were screened with anti-HIF-1␣ or anti-VEGF mAbs, as indicated.
Figure 2 Monotherapies utilizing antisense HIF-1␣ anti-angiogenic therapy, and B7-1-mediated immunotherapy, are only effective against small tumors. Established tumors approximately 0.1 (a) and 0.4 (b) cm in diam-
Vascular attack by antisense HIF-1␣ synergizes with B7-1 immunotherapy to eradicate large tumors We have previously reported 29 that an attack on tumor blood vessels by the flavone acetic acid-related agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in combination with B7.1-mediated immunotherapy overcomes immune-resistance and leads to the eradication of large tumors. Here we consider the possibility that an anti-HIF-1␣ reagent might be a suitable anti-angiogenic substitute for DMXAA in combination therapy, given the toxicity of DMXAA at high therapeutic doses. [33] [34] [35] For combination therapy, 0.4 cm diameter tumors were first injected with DNA/liposome complexes containing 100 g B7-1, followed 48 h later by 100 g antisense HIF-1␣ plasmids. Timed delivery of anti-angiogenic and immunotherapeutic agents has previously proven to be critical to the success of combinational therapy. 29 Combined gene therapy led to complete tumor regression within 10 days, and mice remained tumor-free for 3 weeks (Figure 3 ). To determine whether systemic antitumor immunity had been generated, cured mice were rechallenged with 1 × 10 6 parental tumor cells. Such mice resisted the challenge, and remained tumor-free for at least 2 months (Table 1) , indicating an antitumor immune memory response had been generated.
As a control, B7-1 immunotherapy was combined with an expression plasmid encoding the HIF-1␣ cDNA fragment inserted into pcDNA3 in a sense orientation. In marked contrast to the above results, sense HIF-1␣ could not enhance the therapeutic efficacy of B7-1 (Figure 3) , producing results that were not statistically (P Ͼ 0.05) different from mice treated with B7-1 alone. 
Composition of the effector cell population
We have previously demonstrated that NK cells and CD8 + T cells are largely responsible for B7-1-mediated antitumor immunity. 30 NK cells, and CD8 + and CD4 + T cells are responsible for antitumor immunity generated by combination therapy with antisense HIF-1␣ and B7-1 ( Figure 4 ). In contrast, NK cells are solely responsible for the antitumor effects of anti-sense HIF-1␣ monotherapy, and T cells appear not to be involved.
Antisense HIF-1␣ therapy inhibits VEGF expression, and reduces the density of tumor blood vessels Given that antisense HIF-1␣ down-regulated the expression of HIF-1␣ in EL-4 tumor cells, we sought to determine whether the expression of downstream effectors such as VEGF was abolished. Expression of VEGF was specifically reduced in response to antisense HIF-1␣, as determined by immunohistochemical staining of tumor sections (Figure 1 , compare e and f), and Western blot analysis of tumor homogenates (Figure 1j ), resulting in a statistically significant (P Ͻ 0.01) 30% reduction in tumor vessel density (Figure 1 , compare g and h; Figure 5a ), compared with mock treatment with empty vector. The median and 90th centile distances to the nearest anti-CD31 mAb-labelled venules from an array of points within tumors treated with antisense HIF-1␣ were significantly (P Ͻ 0.05) longer than those in tumors treated with empty vector (Figure 5b) . Tumor blood vessels present after antisense HIF-1␣ therapy were small and poorly formed (Figure 1, compare g and h) .
Discussion Strategies that target HIF-1 have therapeutic potential in treating cancer
The impetus for the present study stemmed from a previous report in which we demonstrated that immune
Figure 4 Immune cell subsets responsible for antitumor immunity. Mice were treated with anti-CD4 (GK1.5), anti-CD8 (53-6.72), and anti-NK cell (PK136) mAbs 4 days before gene transfer, and every alternate day for the duration of the experiment. The size (cm) of tumors was monitored for 21 days following gene transfer. Anti-CD8 and anti-NK mAbs almost completely abrogated tumor rejection in response to B7-1, and combination B7-1/antisense HIF-1␣ therapy, whereas the efficacy of anti-sense HIF-1␣ monotherapy was dependent on NK cells.
resistance of tumors can be overcome by combining B7-1 immunotherapy with a concerted attack on the tumor vasculature delivered by the drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA). 29 In the present study we sought to determine whether anti-HIF-1␣ reagents would be suitable substitutes for DMXAA in combination with B7-1-mediated immunotherapy, given the high toxicity of DMXAA.
Here we have demonstrated for the first time that gene transfer of antisense HIF-1␣ vectors into established tumors is able to cause the complete regression of small tumors. While tumors did not reappear for 3 weeks after complete regression, we cannot discount the possibility that they had regressed to microscopic dormant nodules, rather than being completely eradicated, as occurs with repeated anti-angiogenic therapy employing angiostatin 36 and endostatin. 37 The complete and permanent regression of tumors in response to a single injection of 
). n, number of tumors assessed. A significant difference in mean vessel counts between tumors treated with antisense HIF-1␣ versus pcDNA3 (P Ͻ 0.01) is donated by stars. (b) Histograms showing the median and 90th centile distance to the nearest anti-CD31 mAb-stained vessel from an array point within each tumor. The mean values for tumors treated with pcDNA3 and anti-sense HIF-1␣ are given (±s.d.). n, number of tumors assessed. A significant difference in the median or 90th centile distance to the nearest blood vessels of tumors treated with antisense HIF-1␣ versus pcDNA3 (both P Ͻ 0.05) is donated by stars.
antisense HIF-1␣ is unusual for an anti-angiogenic agent, given that such agents normally cause only transient tumor regression. By some unknown mechanism, anti-HIF-1␣ therapy appears to render tumors susceptible to an attack by NK cells, yet it does not stimulate T cellmediated antitumor immunity, as does B7-1. Since different angiogenic factors either promote or inhibit NK cell adhesion to endothelium, 38 it is possible that antisense HIF-1␣ therapy shifts the balance in favor of NK cell adhesion to tumor microvessels, and thereby facilitates the access of NK cells to the tumor. Thus the efficacy of antisense HIF-1␣ therapy may arise both from an attack on the tumor vasculature, and enhancement of NK cellmediated immunity.
Anti-sense HIF-1␣ therapy could not cause regression of large (0.4 cm diameter) tumors, but it did delay tumor growth. Similarly, we have consistently found that gene transfer of T cell costimulatory integrin ligands, and B7 molecules, into tumors less than 0.3 cm in diameter causes rapid tumor rejection, whereas tumors become increasingly refractory to treatment as their size increases. 30 Larger tumors appear to actively suppress or avoid the immune response. Our results confirm that immunotherapy employing B7-1 and other CAMs has limited therapeutic use, unless their therapeutic efficacy is improved by combination with other therapeutic modalities.
Antisense HIF-1␣ enhances B7-1-mediated immunotherapy The data demonstrate that antisense HIF-1␣ and B7-1-immunotherapies synergize in causing the rapid rejection of large EL-4 tumors, and generation of potent antitumor systemic immunity; thereby establishing that anti-HIF reagents can substitute for DMXAA as an antivascular agent. Cured mice rechallenged with live EL-4 cells remained tumor-free for at least 3 months. As reported previously, 29 timed delivery of the reagents, where B7-1 vectors are administered first, followed by antisense HIF-1␣ vectors proved to be effective. Antisense HIF-1␣ may facilitate B7-1 immunotherapy by inhibiting tumor cell growth, thereby preventing the outgrowth of escape variants; by rendering tumors susceptible to NK cell attack; and by rendering the tumor accessible to T cells as the tumor begins to disintegrate.
Antisense HIF-1␣ downregulates VEGF expression, and reduces vessel density HIF-1␣ expression was detectable throughout tumors 0.4 cm in diameter, and was almost completely abrogated by antisense HIF-1␣ therapy. HIF-1 contributes to the activation of an array of hypoxia-regulated genes including those for VEGF, erythropoietin, and those of the glycolytic pathway including lactate dehydrogenase A, pyruvate kinase M, enolase 1, phosphoglycerate kinase 1, aldolase A, phosphofructokinase L, and glucose transporter-1. [11] [12] [13] [14] We analyzed VEGF expression to determine whether the activation of HIF-1-dependent gene expression was also abolished by antisense HIF-1␣ therapy. VEGF is a potent endothelial mitogen and permeability factor, commonly expressed in tumors, and has been implicated in both physiologically and pathologically occurring angiogenesis. 39 A critical role for VEGF in tumor growth has been suggested by the inhibition of VEGF-induced tumor growth by blocking antibodies, 40 by administration of antisense VEGF mRNAs, 41 and by a retrovirus encoding a soluble mutant form of the VEGF receptor. 42 Gene transfer of antisense HIF-1␣ down-regulated the expression of VEGF, and inhibited the formation of new blood vessels, as shown by a reduction in blood vessel density. Blood vessels in control tumors appeared larger and more mature than those in tumors treated with antisense HIF-1␣, suggesting that blockade of HIF-1 also impairs the maturation and/or patency of blood vessels.
Although HIF-1 is arguably the most important signalling pathway for tumor survival under hypoxia, other pathways are also activated by oncogenes or stress. Combination therapy that combines a vascular attack with immunotherapy, and simultaneously targets other tumor survival pathways will be the focus of future investigations.
Material and methods
Mice and cell lines Male C57BL/6 mice, 6-8 weeks old, were obtained from the Animal Resource Unit, Faculty of Medicine and Health Science, University of Auckland, Auckland, New Zealand. The EL-4 thymic T cell lymphoma, which is of C57BL/6(H-2b) origin, was purchased from the American Type Culture Collection (Rockville, MD, USA). It was cultured at 37°C in DMEM medium (Gibco BRL, Grand Island, NY, USA), supplemented with 10% fetal calf serum, 50 U/ml penicillin/streptomycin, 2 mm l-glutamine, 1 mm pyruvate.
Expression plasmids
A 320-bp cDNA fragment encoding the 5′-end of HIF-1␣ (nucleotides 152 to 454; GenBank AF003698) was produced through PCR using the IMAGE clone 851237 as a template, and the two primers (5′ GGG GAT CCT CTG GAC TTG TCT CTT TC3′ and 5′ GGG CTC GAG TAA CTG ATG GTG AGC CTC 3′). The fragment was cloned into pGEMT (Promega, Madison, WI, USA), and then subcloned into pcDNA3 (Invitrogen, Carlsbad, CA, USA) at BamHI and XhoI sites in sense orientation, and into pcDNA3B at XhoI and BamHI sites in an antisense orientation. The pcDNA3B expression vector is identical to pcDNA3, except the polylinker is reversed (Lehnert et al,  unpublished) . The expression plasmid B7-1-pCDM8, which contains a 1.2 kb cDNA fragment encoding fulllength mouse B7-1 was constructed from a cDNA clone kindly provided by Dr P Linsley, Bristol-Myers-Squibb, Seattle, WA, USA.
Gene transfer of expression plasmids and measurement of antitumor activity Purified plasmids were diluted in a solution of 5% glucose in 0.01% Triton X-100, and mixed in a ratio of 1:3 (wt:wt) with DOTAP cationic liposomes (Boehringer Mannheim, Mannheim, Germany), which is an efficient transfection vehicle. 30 Final plasmid concentration was 1 mg/ml. Tumors were established by injection of 2 × 10 5 EL-4 tumor cells into the right flank of mice, and growth determined by measuring two perpendicular diameters. Animals were killed when tumors reached more than 1 cm in diameter, in accord with Animal Ethics Approval (University of Auckland). Tumors reached 0.1 and 0.4 cm in diameter after approximately 14-18 days, and were injected with 100 l expression plasmid (100 g). For combinational treatment, reagents were delivered in a timed fashion, as described previously. 30 Thus, B7-1 cDNA was injected first, followed by antisense HIF-1␣ cDNA 48 h later. Empty vectors served as control reagents. Cured mice were rechallenged 3 weeks after the disappearance of tumors by injecting 1 × 10 6 EL-4 cells subcutaneously into the opposing flank (left flank). All experiments included six mice per group, and each experiment was repeated at least once.
Gene Therapy
Immunohistochemistry Tumor cryosections (10 m) were prepared 2 days following gene transfer, treated with acetone, rinsed with PBS, and blocked with 2% BSA for 2 h. The sections underwent a overnight incubation with either a hamster anti-B7-1 mAb (1G10, Pharmingen, San Diego, CA, USA), mouse anti-mouse HIF-1␣ mAb (H1␣67, Novus Biologicals, Littleton, CO, USA), or rabbit polyclonal antibodies against VEGF (Ab-1, Lab Vision, CA, USA). They were subsequently incubated for 30 min with appropriate secondary antibodies, using the VECTASTAIN Universal Quick kit (Vector Laboratories, Burlingame, CA, USA); and developed with Sigma FAST DAB (3,3′-diaminobenzidine tetrahydrochloride) and CoCl 2 enhancer tablets (Sigma). Sections were counterstained with Mayer's hematoxylin, mounted and examined by microscopy.
Assessment of vascularity
Sections (10 m) were cut from fresh frozen tumors 4 days following gene transfer. Slides were immunostained with the anti-CD31 antibody, MEC13.3 (Pharmingen), as above. The method for assessment of blood vessel density was as described. 15 Briefly, 40× high power magnification fields (0.155 mm 2 ) were blindly and randomly chosen for blood vessel counts. Blood vessels stained with anti-CD31 mAb were recorded for five fields, and the mean of the highest three counts per surface area (0.155 mm 2 ) was calculated. The concentric circles method 43, 44 was used to assess vascularity.
Western blotting
Tumors previously injected with anti-sense HIF-1␣, sense HIF-1␣, or empty plasmid were excised, and homogenized in lysate buffer (50 mmol/l Tris pH 7.4, 100 mol/l EDTA, 0.25 mol/l sucrose, 1% SDS, 1% NP40, 1 g/ml leupeptin, 1 g/ml pepstatin A and 100 mol/l phenylmethylsulfonylfluoride) at 4°C using a motordriven Virtus homogenizer (Virtus, Gardiner, NY, USA). Tumor lysates from each group of mice were pooled, and cell debris removed by centrifugation at 10 000 g for 10 min at 4°C. Samples containing 100 g protein per well were resolved on 10% polyacrylamide SDS gels under reducing conditions, and electrophoretically transferred to nitrocellulose membrane (Hybond C extra; Amersham Life Science Buckinghamshire, UK). Blots were stained with Ponceau S to ensure correct transfer of proteins. After blocking the membranes with 3% BSA in TBS-T (20 mmol/l Tris, 137 mmol/l NaCl pH 7.6 containing 0.1% Tween-20) for 2 h at room temperature, the blots were incubated with either anti-mouse HIF-1␣ mAb (H1␣67, Novus Biologicals), or a rabbit polyclonal antibody against VEGF (Ab-1, Lab Vision). The membranes were subsequently incubated with horseradish peroxidase-conjugated secondary antibodies, and immunoreactivity detected by enhanced chemiluminescence (Amersham), and exposure to X-ray film.
Depletion of leukocyte subsets
Mice were depleted of CD8 + and CD4 + T cells, and NK cells by i.p. and i.v. injection 4 days before gene transfer, and thereafter every alternate day with 300 g (0.1 ml) of the 53-6.72 (anti-CD8), Gk1.5 (anti-CD4), and PK136 (anti-NK) mAbs. Rat IgG (Sigma) was used as a control antibody. Antibodies were ammonium sulphate fractions of ascites, which titered to at least 1:2000 by FACS (Becton Dickinson, San Jose, CA, USA) staining of splenocytes. Depletion of individual leukocyte subsets was found to be more than 90% effective, as determined by FACScan analysis.
Statistical analysis
Results were expressed as mean values ± standard deviation (s.d.), and a Student's t test was used for evaluating statistical significance. A value of P Ͻ 0.05 was used for statistical significance.
